For Research Purposes Only

Cycle Guide

Weight Loss Peptide Cycle Guide

Weight loss peptide cycling differs from other peptide categories because GLP-1 agonists are typically used long-term rather than in traditional on/off cycles. However, strategic cycling of adjunct compounds alongside GLP-1 therapy can optimize outcomes.

Key Points

GLP-1 agonists: long-term use, not traditional cycling
Weight regain is the primary challenge after discontinuation
Resistance training essential to preserve lean mass
Adjunct compounds can be cycled alongside GLP-1 therapy
Dose reduction (not elimination) may work for maintenance

Step-by-Step Guide

1

GLP-1 Agonist Phase

Semaglutide or tirzepatide following standard titration over 16-20 weeks to maintenance dose. This is typically long-term or indefinite treatment rather than a cycle. Weight regain occurs in most people after discontinuation.

2

Body Composition Optimization

During GLP-1 treatment, add resistance training to preserve lean mass. GLP-1 agonists cause 25-40% lean mass loss alongside fat loss. Adequate protein intake (1.2-1.6 g/kg) is critical.

3

Consider Adjunct Compounds

Some protocols add AOD-9604 (300-500 mcg/day) or 5-Amino-1MQ (50-150 mg/day) as adjuncts targeting different fat metabolism pathways. These can be cycled 8-12 weeks on, 4 weeks off alongside ongoing GLP-1 therapy.

4

Maintenance Phase

Once target weight is reached on GLP-1 agonist, the dose may be reduced (not eliminated) for weight maintenance. Some patients maintain on lower doses (e.g., semaglutide 1.0 mg instead of 2.4 mg).

5

Discontinuation Planning

If GLP-1 discontinuation is planned, taper gradually rather than stopping abruptly. Implement aggressive lifestyle interventions (calorie tracking, exercise program, behavioral support) before and during taper to minimize regain.

Warnings & Precautions

  • !GLP-1 agonists are typically indefinite treatments—not traditional cycles.
  • !Weight regain of 50-66% is common within 1 year of stopping.
  • !Lean mass loss requires active countermeasures (resistance training, protein).
  • !Adjunct compound evidence is much weaker than for GLP-1 agonists.

Frequently Asked Questions

Can I cycle on and off semaglutide?

Not recommended. Clinical data shows most patients regain 2/3 of lost weight within 1 year of stopping. GLP-1 agonists are considered long-term treatments, similar to blood pressure or cholesterol medications. Discuss with your physician before stopping.

How do I minimize weight regain if I stop?

Taper gradually, maintain high protein intake, continue resistance training, track calories carefully, and consider behavioral support. Even with optimal strategies, some regain is likely. Starting these habits while still on the medication builds the foundation.

Do adjunct peptides like AOD-9604 add meaningful benefit?

The evidence for adjunct compounds alongside GLP-1 therapy is very limited. GLP-1 agonists alone produce 15-24% weight loss, which is already dramatic. The marginal benefit of adding weaker compounds is unclear and adds cost and complexity.

Related Protocols

Disclaimer: Protocol information is for educational purposes only. Not medical advice. Consult healthcare professionals.